DOCSLIB.ORG

Antibiotics Used in Human Medicines in the EU

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotics Used in Human Medicines in the EU Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products Annex I Antibiotics authorised for Therapy in Food Producing Animals in the EU (Tables 6 - 10) ãEMEA 1999 Annex I - Antibiotics used in Veterinary Medicine (January 1999) TABLE 6 ANTIBIOTICS AUTHORISED FOR FOOD PRODUCING ANIMALS IN THE EU - ORAL USE Combination of active IT F SP EL PO UK IRE BE NL AU DE DK FIN SW Use in ingredients Humans b-lactam Penicillins B / P / A P P P B / P / A + Ampicillin / Amoxycillin B / P / A B / P / A B / P / A B / P /A B / P / A B / P / A / F B / P / A / F P / A B / P / A B / P B / P / A B / P / F B / P B / P + Amoxycillin+clavulanic acid B B / A P B B B B + Isoxazolyl - Penicillins B / P B + (Met/Oxa/Di/Cloxa/Naf) Cephalosporins B / P P + / related Aminoglycosides Dihydro / Streptomycin B / P B / P / A B B / P B / P / A B / P / A B B / P + / related Neomycin B / P / A B / P / A B / P / A A B / P / A B / P / A B / P / A B / P B / P / A B / P / A B / P / A B / P / A related Kanamycin B / P P A + Gentamicin P B B / P P B / P B / P B / P P + / related Apramycin B / P / A B / P B / P / A B / P / A B / P / A B/ P / A B / P / A B / P P B / P P + Spectinomycin P / A P / A B / P / A P / A P / A B/ P / A P / A P / A B / P / A P / A B / P / A P / A related Framycetin B / P / A B / P / A + Aminosidine (=Paromo-) B / P / A B / P / A B / P / A + Tetracyclines Oxy/ Chlor/ Tetracycline B / P / A / F B / P / A / F B / P / A B / P / A B / P / A / F B / P / A / F B / P / A / F B / P / A / F B / P / A B / P / A / F B / P / A / F B / P / A B / P / A /F5) + / related Doxycycline B / P / A B / P / A B / P / A B / P / A A B / P B / P / A + Lincosamides B / P / A P / A P / A P / A P / A B / P / A P / A P / A B / P / A P B / P / A P / A P + / related Macrolides Tylosin/Spira-/Erythromycin B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A P + / related Tilmicosin P P / A P P P P related Kitasamycin B / P / A A NO Josamycin A B / P / A + Tiamulin P / A P / A P / A P / A P / A P P P / A P / A P / A P / A P P P NO Valnemulin P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) P 4) Polypeptide Antibiotics Polymyxin B / Colistin B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P + / related Bacitracin B / P / A P B / P / A + P = porcine; B = bovines; A = avian; F = Fish ãEMEA 1999 PAGE 1 OF 15 Annex I - Antibiotics used in Veterinary Medicine (January 1999) TABLE 6 - cont. ANTIBIOTICS AUTHORISED FOR FOOD PRODUCING ANIMALS FOR IN THE EU - ORAL USE Combination of active IT F SP EL PO UK IRE BE NL AU DE DK FIN SW Use in ingredients Humans Trimethoprim P / A F5) + Trimethoprim + Sulphonamide B / P / A / F B / P / A / F B / P / A B / P / A B / P / A / F B / P / A / F B / P / A B / P / A B / P / A B / P / A B / P / A / F B / P / F B / P B / P + Baquiloprim + Sulphonamide B B / P B B B B B related Sulphonamides B / P / A / F B / P / A / F B / P / A B / P / A B / P / A B / P B / P / A B / P / A B / P / A B / P / A B / P / A / F B / P / A B / P B / P/ F5) +/ related Quinolones Nalidixic acid B / P / A B / P / A P / A + / related first authorised in 1980 1979 Flumequin B / P / A / F B / P / A / F B / P / A B / A B / A A / F B / P / A / F F5) + / related 2) first authorised in 1989 < 1990 1979 1988 (1982) 1980 Oxolinic acid B / P / A B / P / A / F B / P / A B / P / A B / P / A F F A F F F5 + first authorised in 1988 < 1990 1988 1990 1983 1996 1990 1994 Pipemidic acid B / A B / A + first authorised in 1987 Fluoroquinolones Enrofloxacin B / P / A B / A B / P / A 3) B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A B / P / A P 6) A Related first authorised in 1989 1991 1986 1990 1993 1988 1987 1992 1991 1991 1992 1988 Marbofloxacin 1) 1) B 1) 1) 1) related first authorised in (1993) 2) 1995 2) 2) 4) 4) 4) 4) 4) 4) 4) 4) 4) 4) 4) (1998) (1998) 3) 4) Difloxacin A A A A A A A A A A A4) A4) A A related first authorised in 1998 1998 1998 1998 1998 1998 1998 1998 1998 1998 1998 1998 1998 1998 3) Danofloxacin A A 3) related A first authorised in 2) 2) 2) 2) 2) 2) (1996) (1993) (1997) (1996) 1996 (1993) (1996) Sarafloxacin A F F + (in USA) first authorised in 1997 Orbifloxacin 1) first authorisation 19981) Fenicols Thiamphenicol B / P / A + Miscellaneous Virginiamycin P / A related ) Authorised for companion animals 2) Authorised in food producing animals for parenteral use only 3) Authorised, but not on the market ) No information, whether on the market 5) Sweden: Use in fish only with special permission 6) Finland: Oral use of enrofloxacin in pigs was withdrawn in 1999 P = porcine; B = bovines; A = avian; F = Fish ãEMEA 1999 PAGE 2 OF 15 Annex I - Antibiotics used in Veterinary Medicine (January 1999) TABLE 7 A: ANTIBIOTICS AUTHORISED FOR THERAPY IN CATTLE IN THE EU (all routes of administration) Active Ingredient I F SP EL PO UK IRE BE NL GER AU DK SW FIN b-lactam Penicillins I, M I, M,T O, I, M, T I, M I, M I, M I, M I, M I, M O, I, M, T, U I, U, M I, M, T, U I, M I, M Ampicillin / Amoxycillin O, I, M O, I, M, U O, I, M O, I, U, M O, I, M O, I, O, I, M I, M O, I, M O, I, U, M O, I, M, U O, I, M O O, I, M Amoxyc. + Clavulanicac. I O, I, M O, I M O, I O, I, M O, I I O Isoxazolyl - Penicillins I, M M, U, T O, I, M I, M M M, T M, T M M I, M, U, T O, I, M, U,T M M (Met/Oxa/Di/Cloxa/Naf) Cephalosporins I, M I, M, U O, I, M I, M I, M I, M, T I, M I, M I, M, U M, I I, M, U M, I I M Aminoglycosides Dihydro / Streptomycin O, I, M I, M, U O, I I I, M I, M O, I, M I, M I, M O, I, M, U, T O, I, M, U O, I, M, U, T O, I, M O, I, M Neomycin O, T, M, U O, M O, I, M,T I, M O, M, T O, M, T O, M, T O, I, M O, I, M,T O, I, M, U, T O, I, M, U O, M M Kanamycin O, I, T, M I, I, M I I M I, M I, M, T I, U, M I Gentamicin I O, I, M, O, I, M I I, U, M I O, I, T O, I, U, M O, I Apramycin O, I O, I O, I O, I O, I O, I O, I O, I O Spectinomycin I I O, I I I O, I I I O, I O, I I Framycetin M O, I O, I, M, T M M I, M M M I, M M M M M Aminosidine (=Paromo-) O, I, M, T I O, I O, I Amikacin I Tetracyclines Oxy/Chlor/Tetracycline O, I, U O, I, M, T, U O, I, T, M O, I, U, T O, I, M, U,T O, I, M, T O, M, I, U,T I, T, U O, I, U,T O, I, M, U, T O, I, U, T O, M, I, U O, I O, I, T, M Doxycycline O, I O O, I O I O O, I Lincosamides O, I I, U I, M I, M I, M O, I I I, M O, I, M O, I Macrolides Tylosin/Erythro-/Spiramycin O, I, M O, I, M O, I, M O, I, M O, I O, I, M O, M O, I O, I, M O, I, M O, I O, I I O, I, M Tilmicosin I I I I I I I I I I Oleandomycin M M M M M I M Kitasamycin O, I Josamycin O Tiamulin Polypeptid Antibiotics Polymyxin B / Colistin O, I O, I, M O, I, M O, I, T O, I, M, T O, I, M O, I, M O, I, M, U U, M O Bacitracin I O M O M O = oral; I = Injection; U = intrauterine; M = intramammary; T = topical ãEMEA 1999 PAGE 3 OF 15 Annex I - Antibiotics used in Veterinary Medicine (January 1999) TABLE 7 A - contin.: ANTIBIOTICS AUTHORISED FOR THERAPY IN CATTLE IN THE EU (all routes of administration) Active Ingredient I F SP EL PO UK IRE BE NL GER AU DK SW FIN Trimethoprim I M Trimethoprim + Sulphonamide O, I, M O, I, O, I, M O, I O, I, M, U O, I O, I O, I O, I O, I O, U O, I O, I O, I Baquiloprim + Sulphonamide O, I O, I O, I O O O O, I Sulfonamides O, I, T O, I, U, T O, I, M, T O, I O, I, M, U O, I O, I, T O, I O, I, M O, I, M, U, T O, I, T O, I, U, T O, I, T O, I, T Quinolones Nalidixic acid O O Flumequin O, I O, I O, I O O, I I O, I Oxolinic acid O O O O O Pipemidic acid O O Fluoroquinolons Enrofloxacin O, I O, I O, I O, I O, I O, I O, I O, I O, I O, I, U O, I, U O, I I I Marbofloxacin I O, I I I Danofloxacin I I I I I I I I I Fenicols Florfenicol I I I I I I I I I I I I Thiamphenicol O, I, U T T Miscellaneous Novobiocin M M M M M M M M M Rifampicin M, U M U M O = oral; I = Injection; U = intrauterine; M = intramammary; T = topical ãEMEA 1999 PAGE 4 OF 15 Annex I - Antibiotics used in Veterinary Medicine (January 1999) TABLE 7 B: ANTIBIOTICS AUTHORISED FOR ORAL USE IN CATTLE IN THE EU Active Ingredient I F SP EL PO UK IRE BE NL GER AU DK SW FIN b-lactam Penicillins X X Ampicillin / Amoxycillin X X X X X X X X X X X X X Amoxyc.
Load more

Recommended publications
  • Microbiological Profile of Telithromycin, the First Ketolide Antimicrobial
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Paperprovided by 48Elsevier Disc - Publisher Connector Microbiological profile of telithromycin, the first ketolide antimicrobial D. Felmingham GR Micro Ltd, London, UK ABSTRACT Telithromycin, the first of the ketolide antimicrobials, has been specifically designed to provide potent activity against common and atypical/intracellular or cell-associated respiratory pathogens, including those that are resistant to b-lactams and/or macrolide±lincosamide±streptograminB (MLSB) antimicrobials. Against Gram- positive cocci, telithromycin possesses more potent activity in vitro and in vivo than the macrolides clarithromycin and azithromycin. It retains its activity against erm-(MLSB)ormef-mediated macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes and against Staphylococcus aureus resistant to macrolides through inducible MLSB mechanisms. Telithromycin also possesses high activity against the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis, regardless of b-lactamase production. In vitro, it shows similar activity to azithromycin against H. influenzae, while in vivo its activity against H. influenzae is higher than that of azithromycin. Telithromycin's spectrum of activity also extends to the atypical, intracellular and cell-associated pathogens Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae. In vitro, telithromycin does not induce MLSB resistance and it shows low potential to select for resistance or cross-resistance to other antimicrobials. These characteristics indicate that telithromycin will have an important clinical role in the Ahed empirical treatment of community-acquired respiratory tract infections. Bhed Clin Microbiol Infect 2001: 7 (Supplement 3): 2±10 Ched Dhed Ref marker Fig marker these agents. Resistance to penicillin, particularly among S.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • Ketek, INN-Telithromycin
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSlonger no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Ketek 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg of telithromycin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light orange, oblong, biconvex tablet, imprinted with ‘H3647’ on one side and ‘400’ on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications authorised When prescribing Ketek, consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1). Ketek is indicated for the treatment of the following infections: longer In patients of 18 years and older: • Community-acquired pneumonia, mild or moderate (see section 4.4). • When treating infections caused by knownno or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1): - Acute exacerbation of chronic bronchitis, - Acute sinusitis In patients of 12 years and older: • Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriateproduct in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1). 4.2 Posology and method of administration Posology The recommended dose is 800 mg once a day i.e. two 400 mg tablets once a day. In patients of 18 years and older, according to the indication, the treatment regimen will be: - Community-acquired pneumonia: 800 mg once a day for 7 to 10 days, Medicinal- Acute exacerbation of chronic bronchitis: 800 mg once a day for 5 days, - Acute sinusitis: 800 mg once a day for 5 days, - Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
    [Show full text]
  • Backyard Chickens in the Consult Room
    BACKYARD CHICKENS IN THE CONSULT ROOM Michael Cannon BVSc, MACVSc, Grad DipEd Cannon and Ball Veterinary Surgeons 461 Crown Street, West Wollongong In recent years clients are arriving with their chickens and but their expectations have changed ‐ they are wanting them treated as pets rather than as production animals. This means you cannot use common poultry techniques for diagnosis, such as slaughter and post‐mortem. The aim of this short presentation is to give you some tips on what I have found help me deal with this kind of patient. Common Breeds Clients often know the breed of their chickens and they become disappointed if you do not. They feel they know the breed so they know more than you. This embarrassing situation is simply avoided by the receptionist or nurse asking the question and recording the breed on your file. The common breeds that were the basis of many of the common backyard birds and the poultry industry in Australia are: Australorp and the White Leghorn. There are many other commonly encountered Show Poultry breeds such as : Silkie Bantam; White Sussex; Araucana, Ancona; Pekin (the true bantam): ISA Brown; Australian Game; Cochin; Barnevelder; White Polish; Minorca; Rhode Island Red and New Hampshire. Some Quick Facts •Many Backyard chickens live approximately 8‐10 years •They have only three good productive years • 70% of the cost of raising chickens is spent on feed •In monogastric animals, like chickens, energy comes mainly from carbohydrates and fats since fibre containing cellulose cannot be digested •White eggs are laid by chickens with white ear lobes, while brown eggs are laid by chickens with red ear lobes.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • Veterinary Use of Antibiotics Highly Important to Human Health
    VETERINARY USE OF ANTIBIOTICS HIGHLY IMPORTANT TO HUMAN HEALTH The World Health Organization, the Food withholding periods and export and Agriculture Organization and the slaughter intervals in the case of food- World Organization for Animal Health producing animals. Where possible, are working to protect the effectiveness choices should be based on culture and of antimicrobials in the face of rapidly susceptibility testing and the narrowest increasing resistance in serious and life- spectrum drugs effective against the threatening pathogens. infection. Antimicrobial use in animals contributes Alternatives to antimicrobial use — such to the selection and spread of resistance. as changes in husbandry, management, Veterinarians must help preserve vaccination and infection prevention existing antibiotics and fight the serious and control — should also be explored public health threat of antimicrobial in each case. The overriding principle resistance. Veterinarians need to of antimicrobial prescribing is to use carefully consider how they prescribe as little as possible but as much as antibiotics, especially those that are necessary to address the infection. critical in human medicine, to help Following diagnosis, consider using preserve these lifesaving drugs for the the first line antimicrobials along with future. alternative treatment approaches. The table on the next page outlines Second line use should be limited where in a broad and general sense how possible to when susceptibility testing or veterinarians should use the antibiotics clinical results have proven that first line highly important to human medicine identified by the Australian Strategic antibiotics are not effective. and Technical Advisory Group on Third line antimicrobials are for AMR (ASTAG). Responsible use of use as a last resort.
    [Show full text]